Method for preparation of aluminum hydroxyphosphate adjuvant
View Patent ↗The present invention relates to methods for preparing amorphous aluminum hydroxyphosphate. An aluminum salt and a phosphate solution are co-mixed at a constant ratio in the presence of a buffer. Preferably, an excess of the phosphate solution is used to act as a buffer. Due to the presence of a buffer, the pH is maintained constant during reaction (after initial rapid equilibration) without active adjustment. The methods are particularly applicable for the large scale manufacturing of aluminum phosphate adjuvant. Aluminum phosphate is used as an adjuvant in vaccine formulations, particularly those including a protein or saccharide antigen.
1. A method for the preparation of aluminum hydroxyphosphate adjuvant comprising the steps of:
(a) co-mixing a solution of an aluminum salt with a solution of a phosphate at a defined P/Al molar ratio to precipitate aluminum hydroxyphosphate adjuvant in the presence of a buffer that maintains a constant pH, wherein said co-mixing involves the simultaneous and continuous combining of the solution of an aluminum salt and the solution of a phosphate and the defined P/Al ratio is in the range of 2.0-3.5; and
(b) buffer exchanging with a buffer exchange solution to remove at least 80% of any excess phosphate, buffer or other residual salts from the original reactants.
2. The method of claim 1 , wherein the solution of phosphate is selected from the group consisting of sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, phosphoric acid, potassium phosphate monobasic, potassium phosphate dibasic, potassium phosphate tribasic, ammonium phosphate monobasic, ammonium phosphate dibasic, ammonium phosphate tribasic, ammonium sodium phosphate, and combinations thereof.
3. The method of claim 1 , wherein the solution of phosphate has a pH from 7.4 to 12.4, 8.0 to 10.0, or 8.5 to 9.5.
4. The method of claim 1 , wherein the solution of phosphate comprises sodium phosphate dibasic.
5. The method of claim 1 , wherein the aluminum salt is selected from the group consisting of aluminum chloride, potassium aluminum sulfate, aluminum ammonium sulfate, aluminum nitrate, aluminum bromide, aluminum bromate, aluminum chlorate, aluminum iodide, and different hydrate forms of these.
6. The method of claim 5 , wherein the aluminum salt is aluminum chloride hexahydrate.
7. The method of claim 1 , wherein the aluminum hydroxyphosphate adjuvant has one or more of the following properties:
zeta potential Point of Zero Charge (PZC) from 4.2 to 6.9, from 4.7 to 6.4, or 4.7 to 5.4;
aggregate particle size volume median diameter, d(v,0.5), less than 40 microns, from 2 to 10 microns, or from 3 to 6 microns;
pH in the range of 3.0 to 8.0, 4.5 to 7.2, or 4.5 to 5.5; or
P/Al molar ratio measured in the precipitated aluminum hydroxyphosphate adjuvant of 0.6-1.2; 0.8-1.2 or 0.9-1.1.
8. The method of claim 7 , further comprising performing size reduction prior to step (b) to reduce the aggregate particle size volume median diameter (d(v,0.5)) from about 10 to 40 microns to about 2 to 10 microns or 3 to 6 microns.
9. The method of claim 8 , wherein performing the size reduction is by use of a high-shear rotor-stator mixer, vigorous mixing with an impeller, or recirculating through a pump.
10. The method of claim 1 , wherein the buffer exchange solution for buffer exchanging is saline or histidine.
11. The method of claim 1 , wherein the buffer exchange step is carried out by ultrafiltration.
12. The method of claim 11 , wherein the extent of ultrafiltration buffer exchange is 4 to 15 diavolumes or 5 to 7 diavolumes.
13. The method of claim 1 , further comprising sterilizing the aluminum hydroxyphosphate adjuvant after step (b).
14. The method of claim 13 , wherein said sterilizing is by autoclaving or in-situ steam sterilization.